Puromycin Dihydrochloride
Puromycin Dihydrochloride
Gibco™

Puromycin Dihydrochloride

Puromycin Dihydrochloride is an aminonucleoside antibiotic produced by Streptomyces alboniger. Puromycin works by inhibiting peptidyl transfer on both prokaryotic andRead more
Catalog NumberQuantity
A111380310 x 1 mL
A111380220 mL
Catalog number A1113803
Price (JPY)
48,400
Each
Contact Us ›
Quantity:
10 x 1 mL
Puromycin Dihydrochloride is an aminonucleoside antibiotic produced by Streptomyces alboniger. Puromycin works by inhibiting peptidyl transfer on both prokaryotic and eukaryotic ribosomes; resistance is conferred by the expression of the pac gene.

Puromycin is widely used in cell biology as a selection antibiotic agent in mammalian cell culture systems. The recommended working concentration ranges from 0.2–5.0 μg/mL, although it can be toxic to eukaryotic cells at concentrations as low as 1 μg/mL. Gibco™ Puromycin Dihydrochloride is supplied at 10 mg/mL in 20 mM HEPES buffer (pH 6.2–6.8) in 10 vials each containing 1 mL.

Other Choices and More Information
We offer a wide range of antibiotics and antimycotics in both powder and liquid formats.

See the complete list, or find products for:
Contamination control
Eukaryotic and bacterial selection

See recommendations for working concentrations for selection antibiotics.

Learn more about the use of antibiotics and antimycotics in cell culture, and review guidelines for decontaminating cultures.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Concentration10 mg/mL
Culture TypeMammalian Cell Culture, Insect Cell Culture
For Use With (Application)Eukaryotic Selection⁄Stable Cell Line Generation
Product LineGibco
Quantity10 x 1 mL
Shelf Life12 Months
Shipping ConditionDry Ice
FormLiquid
Product TypeAntibiotic
SterilitySterile-filtered
With AdditivesHEPES
Unit SizeEach
Contents & Storage
Storage conditions: -5 to -20°C
Shipping conditions: Frozen
Shelf life: 12 months from date of manufacture

Frequently asked questions (FAQs)

Which of your antibiotics (Geneticin, Zeocin, Hygromycin B, Blasticidin, and Puromycin) can be used together for stable selection in mammalian cells?

All of our antibiotics (Geneticin, Zeocin, Hygromycin B, Blasticidin, and Puromycin) can be used together for making multiple stable cell lines. However, kill curves will need to be performed for each combination of antibiotics since sensitivity to a given antibiotic tends to increase when combined with other antibiotics.

How light-sensitive is Puromycin Dihydrochloride?

Puromycin Dihydrochloride is light sensitive on par with the light sensitivity of most basal media like DMEM and RPMI 1640. We would recommend limiting exposure of this product to light as much as possible (i.e,. don't leave on the bench or under hood lights longer than necessary). That said, using a light microscope to observe cells under normal conditions and timeframes will not break down the antibiotic.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

How can I decontaminate my cultures?

When an irreplaceable culture becomes contaminated, researchers may attempt to eliminate or control the contamination.

1. Determine if the contamination is bacteria, fungus, mycoplasma, or yeast. Read more here to view characteristics of each contaminant.
2. Isolate the contaminated culture from other cell lines.
3. Clean incubators and laminar flow hoods with a laboratory disinfectant, and check HEPA filters.
4. Antibiotics and antimycotics at high concentrations can be toxic to some cell lines. Therefore, perform a dose-response test to determine the level at which an antibiotic or antimycotic becomes toxic. This is particularly important when using an antimycotic such as Gibco Fungizone reagent or an antibiotic such as tylosin.

The following is a suggested procedure for determining toxicity levels and decontaminating cultures:

1. Dissociate, count, and dilute the cells in antibiotic-free media. Dilute the cells to the concentration used for regular cell passage.
2. Dispense the cell suspension into a multiwell culture plate or several small flasks. Add the antibiotic of choice to each well in a range of concentrations. For example, we suggest the following concentrations for Gibco Fungizone reagent: 0.25, 0.50, 1.0, 2.0, 4.0, and 8.0 µg/mL.
3. Observe the cells daily for signs of toxicity such as sloughing, appearance of vacuoles, decrease in confluency, and rounding.
4. When the toxic antibiotic level has been determined, culture the cells for two to three passages using the antibiotic at a concentration one- to two-fold lower than the toxic concentration.
5. Culture the cells for one passage in antibiotic-free media.
6. Repeat step 4.
7. Culture the cells in antibiotic-free medium for four to six passages to determine if the contamination has been eliminated.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What antibiotics do you offer to help control or eliminate cell culture contamination?

Please view the following page to browse the cell culture antibiotics we offer (https://www.thermofisher.com/us/en/home/life-science/cell-culture/mammalian-cell-culture/antibiotics.html).

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Citations & References (9)

Citations & References
Abstract
Trop2 Promotes Multidrug Resistance by Regulating Notch1 Signaling Pathway in Gastric Cancer Cells.
Authors:Kuai X, Jia L, Yang T, Huang X, Zhao W, Zhang M, Chen Y, Zhu J, Feng Z, Tang Q
Journal:Med Sci Monit
PubMed ID:31964857
'BACKGROUND Chemotherapy is widely used in gastric cancer treatment, but multidrug resistance remains a leading cause of chemotherapy failure. Trop2 is highly expressed in gastric tumor tissues and greatly influences cancer progression. However, little is known about the relationship between Trop2 and drug resistance in gastric cancer. MATERIAL AND METHODS ... More
mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer.
Authors:Chiang CT, Demetriou AN, Ung N, Choudhury N, Ghaffarian K, Ruderman DL, Mumenthaler SM
Journal:Cancer Lett
PubMed ID:30036610
Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations are often successfully treated with EGFR tyrosine kinase inhibitor (TKI) such as erlotinib; however, treatment resistance inevitably occurs. Given tumor metabolism of glucose and therapeutic response are intimately linked, we explored the metabolic differences between isogenic erlotinib-sensitive and -resistant NSCLC ... More
The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials.
Authors:Sheridan CM, Garcia VE, Ahyong V, DeRisi JL
Journal:Malar J
PubMed ID:30541569
The continued spectre of resistance to existing anti-malarials necessitates the pursuit of novel targets and mechanisms of action for drug development. One class of promising targets consists of the 80S ribosome and its associated components comprising the parasite translational apparatus. Development of translation-targeting therapeutics requires a greater understanding of protein ... More
Cardiac glycosides decrease influenza virus replication by inhibiting cell protein translational machinery.
Authors:Amarelle L, Katzen J, Shigemura M, Welch LC, Cajigas H, Peteranderl C, Celli D, Herold S, Lecuona E, Sznajder JI
Journal:Am J Physiol Lung Cell Mol Physiol
PubMed ID:30892074
Cardiac glycosides (CGs) are used primarily for cardiac failure and have been reported to have other effects, including inhibition of viral replication. Here we set out to study mechanisms by which CGs as inhibitors of the Na-K-ATPase decrease influenza A virus (IAV) replication in the lungs. We found that CGs ... More
Modulating eIF6 levels unveils the role of translation in ecdysone biosynthesis during Drosophila development.
Authors:Russo A, Gatti G, Alfieri R, Pesce E, Soanes K, Ricciardi S, Mancino M, Cheroni C, Vaccari T, Biffo S, Calamita P
Journal:Dev Biol
PubMed ID:31283922
During development, ribosome biogenesis and translation reach peak activities, due to impetuous cell proliferation. Current models predict that protein synthesis elevation is controlled by transcription factors and signalling pathways. Developmental models addressing translation factors overexpression effects are lacking. Eukaryotic Initiation Factor 6 (eIF6) is necessary for ribosome biogenesis and efficient ... More